ISARNA THERAPEUTICS
Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.
ISARNA THERAPEUTICS
Industry:
Biotechnology Medical Therapeutics
Founded:
1998-01-01
Address:
Munich, Bayern, Germany
Country:
Germany
Website Url:
http://www.isarna-therapeutics.com
Total Employee:
11+
Status:
Active
Contact:
49 89 890831 0
Total Funding:
124.22 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Font Awesome Apache Wordpress Plugins
Similar Organizations
Emendo Biotherapeutics
Emendo Biotherapeutics is a biotechnology company
Current Advisors List
Advisor
Advisor
Advisor
Advisor
Advisor
Advisor
Advisor
Advisor
Current Employees Featured
Karl-Hermann Schlingensiepen Founder @ Isarna Therapeutics
Founder
Eugen Leo Clinical Development @ Isarna Therapeutics
Clinical Development
Claus Schalper Chief Executive Officer @ Isarna Therapeutics
Chief Executive Officer
2021-09-01
Katja Wosikowski Head Preclincial Operations @ Isarna Therapeutics
Head Preclincial Operations
René Rückert Chief Operating Officer @ Isarna Therapeutics
Chief Operating Officer
Marion Munk Chief Medical Officer @ Isarna Therapeutics
Chief Medical Officer
Founder
Investors List
Global Asset Fund
Global Asset Fund investment in Venture Round - Isarna Therapeutics
MIG
MIG investment in Venture Round - Isarna Therapeutics
AT Impf
AT Impf investment in Venture Round - Isarna Therapeutics
MIG
MIG investment in Venture Round - Isarna Therapeutics
Global Asset Fund
Global Asset Fund investment in Venture Round - Isarna Therapeutics
MIG
MIG investment in Venture Round - Isarna Therapeutics
Global Asset Fund
Global Asset Fund investment in Venture Round - Isarna Therapeutics
MIG
MIG investment in Venture Round - Isarna Therapeutics
MIG
MIG investment in Venture Round - Isarna Therapeutics
Global Asset Capital
Global Asset Capital investment in Private Equity Round - Isarna Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-30 | Isarna Therapeutics Appoints Claus Schalper as CEO |
Official Site Inspections
http://www.isarna-therapeutics.com
- Host name: sh20024.ispgateway.de
- IP address: 92.205.54.255
- Location: Germany
- Latitude: 51.4476
- Longitude: 7.0122
- Timezone: Europe/Berlin
More informations about "Isarna Therapeutics"
The Company - Isarna Therapeutics
Dr. Rückert joined in 2019 as Chief Operating Officer at Isarna Therapeutics. He is a medical doctor, board-certified in Biochemistry and a trained Immunologist and holds an MBA. ... CRO’s. Chris has served in the position of Finance …See details»
Isarna Therapeutics – Leading Expertise in TGF-ß Biology and …
Isarna Therapeutics was built on profound knowledge in antisense oligonucleotide design and therapeutic development of this innovative compound class. Today, Isarna is developing a …See details»
Isarna Therapeutics - Crunchbase Company Profile & Funding
Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel …See details»
Isarna Therapeutics GmbH - LinkedIn
Isarna Therapeutics is a clinical stage biotech company, headquartered in Munich, Germany. Isarna develops ISTH0036, a next-generation antisense to block TGF-beta 2 production, a key molecule in ...See details»
Isarna Therapeutics Presents Positive Phase 2 BETTER Trial
May 7, 2025 Isarna Therapeutics was built on profound expertise in antisense oligonucleotide design and the therapeutic targeting of the TGF-β signaling axis, a critical driver in a wide …See details»
Isarna Therapeutics 2025 Company Profile: Valuation, …
Isarna Therapeutics is headquartered in Munich, Germany. What is the size of Isarna Therapeutics? Isarna Therapeutics has 8 total employees. What industry is Isarna Therapeutics in? Isarna Therapeutics’s primary industry is Drug …See details»
News & Events - Isarna Therapeutics
June, 2021. Looking beyond the standard of care for eye diseases. Isarna Therapeutics’ antisense therapy targeting transforming growth factor beta 2, ISTH0036, is about to enter …See details»
Isarna Therapeutics - Contacts, Employees, Board Members
Isarna Therapeutics has 6 current employee profiles, including Founder Karl-Hermann Schlingensiepen. Isarna Therapeutics has 9 board members and advisors, including Walter …See details»
Isarna Therapeutics GmbH Overview | SignalHire Company Profile
Isarna Therapeutics GmbH is a private company that has been in the industry for 25 years. The company currently specializes in the Biotechnology area. ... Organization Website: isarna …See details»
Isarna Therapeutics Company Profile - Office Locations ... - Craft
Isarna Therapeutics $122.77 m in total funding,. See insights on Isarna Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Isarna Therapeutics Presents Positive Phase 2 BETTER Trial
Gräfelfing, Germany, May 7 th, 2025 – Isarna Therapeutics presented final positive results from its Phase 2 BETTER trial at the Association for Research in Vision and Ophthalmology (ARVO) …See details»
Isarna Therapeutics - Company info. interviews, news
Isarna Therapeutics has an unmatched commitment to developing TGF-B inhibitors that stimulate the human immune system to effectively fight cancer. They are advancing a unique pipeline of …See details»
Isarna Therapeutics GmbH - Drug pipelines, Patents, Clinical
May 7, 2025 MUNICH--(BUSINESS WIRE)-- Isarna Therapeutics will present an update from its ISTH0036 clinical development program and the ongoing BETTER Study at the EURETINA …See details»
Pipeline - Isarna Therapeutics
ISTH0036 is a locked nucleic acid-modified antisense oligonucleotide selectively targeting the messenger RNA (mRNA) of TGF-β2. Preclinical studies have demonstrated that ISTH0036 is …See details»
Isarna Therapeutics - Overview, News & Similar companies
Nov 30, 2021 Isarna Therapeutics was built on profound knowledge in antisense oligonucleotide design and therapeutic development of this innovative compound cla ss. Today, Isarna is …See details»
Isarna Therapeutics - Products, Competitors, Financials, Employees ...
Isarna Therapeutics presents positive phase 2 trial final results 9 May 2025 × Positive results concept. Isarna’s chief medical officer, Prof. Marion R. Munk, shared data on ISTH0036, a …See details»
Isarna Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Isarna Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 1 news, Disease Domain:Neoplasms, Technology Platform:ASO, Drug:NASH …See details»
Isarna Therapeutics - Funding, Financials, Valuation & Investors
Isarna Therapeutics is a biotechnology company. AI Content may contain mistakes and is not legal, financial or investment advice.See details»
Isarna Therapeutics Presents Positive Phase 2 BETTER Trial Final ...
May 9, 2025 Isarna Therapeutics presented final positive results from its phase 2 BETTER trial at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting on May …See details»
Isarna Therapeutics revolutionizes ophthalmology - Labiotech.eu
May 17, 2024 Isarna Therapeutics has one drug in clinical development, ISTH0036. The company recently presented the first data from its BETTER study, a parallel, two-segment …See details»